The Peter Attia Drive - April 06, 2026


#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance

Topics
Hosted by
Mentioned
#385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more #387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Episode Stats


Length

42 minutes

Words per minute

164.87

Word count

7,035

Sentence count

364

Harmful content

Misogyny

1

sentences flagged

Hate speech

2

sentences flagged


Summary

Summaries generated with gmurro/bart-large-finetuned-filtered-spotify-podcast-summ .

In this episode, I explain what aging clocks are, how they work, and what they may actually tell us about our biological age. I also discuss the limitations of anti-aging clocks, and why they may not be as effective as we think.

Transcript

Transcript generated with Whisper (turbo).
Misogyny classifications generated with MilaNLProc/bert-base-uncased-ear-misogyny .
Hate speech classifications generated with facebook/roberta-hate-speech-dynabench-r4-target .
Topics generated with Qwen2.5-3B-Instruct.
Hosts, guests, and mentioned names generated with spaCy (en_core_web_sm), reconciled against Wikidata.
00:00:00 Hey, everyone. Welcome to the Drive podcast. I'm your host, Peter Atiyah. This podcast,
00:00:16 my website, and my weekly newsletter all focus on the goal of translating the science of longevity
00:00:21 into something accessible for everyone. Our goal is to provide the best content in health and
00:00:26 wellness. And we've established a great team of analysts to make this happen. It is extremely
00:00:31 important to me to provide all of this content without relying on paid ads to do this. Our work
00:00:36 is made entirely possible by our members. And in return, we offer exclusive member only content
00:00:42 and benefits above and beyond what is available for free. If you want to take your knowledge of
00:00:47 this space to the next level, it's our goal to ensure members get back much more than the price
00:00:53 of a subscription. If you want to learn more about the benefits of our premium membership,
00:00:58 head over to peteratiamd.com forward slash subscribe.
00:01:04 Welcome to a special episode of The Drive. In this episode, I take a different approach
00:01:10 where I walk through a single topic in depth. And this is a topic that many of you have been
00:01:15 asking about, aging clocks. So in this episode, I explain what aging clocks are and the difference
00:01:21 between chronological age and biological age, along with the difference between those and
00:01:26 something called the pace of aging, how epigenetic clocks work, and what they may actually be
00:01:31 measuring. I'm going to talk about a randomized control trial that used three very simple
00:01:35 interventions and tested four of the most common aging clocks. I'm going to also talk about another
00:01:41 study that used brain imaging via MRI to study the pace of aging and see what could be gleaned
00:01:50 about not just the risk of dementia, but also mortality. I'll discuss the biggest limitation
00:01:56 in the field, which is whether changing a clock actually changes meaningful clinical outcomes.
00:02:02 So without further delay, I hope you enjoy this special episode of The Drive.
00:02:11 So if you wanted to run the perfect anti-aging trial, you know, the end points would be really
00:02:17 obvious. You'd want to see fewer heart attacks, fewer cancers, fewer dementia diagnoses, and
00:02:24 ultimately fewer deaths. So we would call these hard outcomes real outcomes that matter. These
00:02:29 are the clinical outcomes that we all care about. Now, of course, the reason we don't see these
00:02:33 trials is that they would take a very long time. These would literally be 20-year trials, and with
00:02:41 that would come enormous complexity and cost. Furthermore, it would be very difficult to
00:02:48 ensure that whatever intervention you put in place was being put in place for the duration
00:02:53 of this time. I mean, that would be not that hard to do if it was a drug trial, because it's
00:02:58 relatively easy to take a drug, but it would be more challenging for a lifestyle trial.
00:03:02 Okay. So every few years, the fields of geroscience and medicine and cardiovascular
00:03:09 disease, et cetera, they, they go looking for a proxy or a shortcut. So some intermediate marker
00:03:16 that could move faster than these hard outcomes, but that would still predict the hard outcome
00:03:22 reliably. And I think over the past few years, what we've really seen is that aging clocks
00:03:27 are the most interesting and popular proposed shortcut. Again, I don't use the word shortcut
00:03:34 with a, with a sort of negative connotation. It's like, this is what we need. We do need a
00:03:38 shortcut. We need a proxy. So again, the idea here is pretty compelling, right? Imagine you
00:03:43 could have a single number that would predict your actual aging or your actual biological age
00:03:49 that's different from your chronological age, or maybe a rate of aging that reflects a new
00:03:55 trajectory you're on. This could be very valuable in designing clinical trials or looking at
00:04:00 interventions. And even at the individual level, understanding if you've made a change and is it
00:04:07 making a difference. So think about this as a foray into precision medicine. Now, there's a
00:04:13 little bit of a problem in my mind because these aging clocks are being marketed as the latest and
00:04:18 maybe best way to keep tabs on your health. Lots of people are ordering them. They're available to
00:04:24 anybody. They're sold by longevity docs who promise to improve your biologic age with
00:04:30 groundbreaking, you know, combinations of peptides or other elixirs. But I think it's worth looking
00:04:37 into these a little more closely to understand what the science can actually tell us. And I
00:04:43 think the best way to do this is to look closely at two studies, two very interesting studies,
00:04:49 that can help us get at the fundamental questions that we really want to be asking around this,
00:04:55 which is what is the clinical utility of an aging clock? So before we do that, though,
00:05:02 I just want to kind of make sure everybody's starting from the same footing in terms of
00:05:06 understanding the biological stuff that we're talking about. So what is an aging clock? Well,
00:05:12 basically at its core, it's a prediction model. But let's take a step back. Your chronological age
00:05:19 is also a prediction model. You see, if I told you that in front of me there is a 20-year-old
00:05:25 and there is a 70-year-old, and I asked you to predict which one of those people is going to die
00:05:32 first, I think everybody would, knowing nothing else, make the correct prediction. Now, we could
00:05:38 layer onto that certain other factors. So if I said, okay, well, I actually now have two 70-year-olds
00:05:45 in front of me and one of them has cancer and the other one does not. Do you predict which one of
00:05:51 those is going to live longer than the other? And again, without knowing anything beyond what I told
00:05:55 you, I think everybody would make the same prediction. And so this idea of using information
00:06:01 to predict mortality is not new. It is the entire basis of the actuarial underwriting industry. And
00:06:09 there are companies that are exceptionally good at doing this. These are called life insurance
00:06:14 companies. And their data are incredibly proprietary, and it's really less so their
00:06:19 data and more so what they do with the data that is incredibly proprietary, right? They gather a
00:06:25 lot of information about you. They do a blood draw on you. They know your age. They know various
00:06:31 factors about you. They take your blood pressure, your weight, and things like that, relatively
00:06:36 rudimentary stuff. But from that, they have these tables, again, highly proprietary, that seem to
00:06:42 do a very good job of predicting when you're going to die. And so the question is, would one of these
00:06:47 aging clocks be even better? Okay, so let's talk about how these things work. So they typically
00:06:52 work by starting with some biological data. And the most common thing that we're going to hear
00:06:58 about is epigenetic data. So this is DNA methylation. And then they train an algorithm
00:07:05 to look at that and predict something age-related. So I think it's worth spending a minute on DNA
00:07:11 methylation. I don't want to go far down the rabbit hole on this, but you've undoubtedly
00:07:15 heard the term. And so I just want to make sure everybody's playing from the same level.
00:07:19 So DNA methylation is a way that we, or the way that the body modifies epigenetically what the
00:07:26 DNA expression is. So it doesn't change the sequence of DNA, but it can influence how the
00:07:32 genes are turned on or turned off, right? So that's what we call expression of genes. So
00:07:38 when you modify the epigenome, which is basically when you put a methyl group, so that's a carbon
00:07:45 with three hydrogens, when you put it on the backbone of the DNA, that impacts whether or not
00:07:54 that section of DNA gets turned into RNA. That's what we mean by expression.
00:08:00 You may have heard the term CPG, but not in reference to consumer packaged goods,
00:08:05 but a CPG refers to the location where these methylations most commonly take place. If you
00:08:13 remember back to high school biology, we have these four nucleotides. The C is the abbreviation
00:08:21 for cytosine. And so where these things typically occur is right on the phosphate bond that links
00:08:32 the C, the cytosine, with the G, the guanine nucleotide. So when we talk about CPGs, that's
00:08:40 just kind of another way that people kind of quickly talk about the methylations. So the
00:08:45 methylations that occur at these CPG sites will then affect quite strongly the genes that are
00:08:51 near to those areas. And why we care about this, of course, why I'm even talking about this, is
00:08:57 these methylation levels of many sites actually change somewhat predictably as we age. So this
00:09:04 is kind of the rationale for all of this, right? Is as we age, methylation sites change. Ergo,
00:09:12 if we can measure what's happening at methylation sites, can we impute age? Can we impute something
00:09:20 better than chronologic age? Because remember, chronological age is an awesome predictor as it
00:09:25 stands. But we're asking, can we do better? Because chronologic age is great at telling
00:09:31 you that on average, a 60-year-old is going to live, you know, a shorter duration than a 50-year-old.
00:09:37 But we know that that's not true at the individual level. There are plenty of 50-year-olds that are
00:09:41 going to have a shorter remaining life than plenty of 60-year-olds. It just depends on the individual
00:09:46 health and a whole bunch of other things. So we want to get at that difference. Okay.
00:09:49 it. So these patterns are going to shift gradually over time. And various factors,
00:09:59 behavioral factors, such as smoking, metabolic health, inflammation, actually play a role in
00:10:04 that. And so for this reason, researchers came to the conclusion roughly 10, little over 10 years
00:10:12 ago, that we could use these as kind of a molecular record keeping of what's going on
00:10:19 in the body. And I think that's probably why DNA methylation has created such an important
00:10:27 and foundational part of the clock story. So that's why I kind of went a little deep in the
00:10:33 weeds there. I think it's important. So, you know, you've probably heard of the Horvath clock.
00:10:38 That's one of the earliest first generation clocks, and that was obviously based on this.
00:10:42 So these models were trained on large data sets of DNA methylation, which were measured
00:10:48 and collected from thousands of individuals across a wide age range. And they're mostly
00:10:53 using cross-sectional cohorts rather than tracking an individual over time. Why? Because
00:10:57 as exciting as it would be to track an individual over time, those data sets are somewhat limited
00:11:02 and they're harder to get. Whereas if you take very large cohorts where you just slice the
00:11:07 population, you would get access to 20 year olds, 25 year olds, 30 year olds, 50 year olds, 60 year
00:11:12 olds, 70 year olds, 90 year olds, et cetera. And the hope would be that, Hey, we're going to see
00:11:17 what the signature of methylation is, you know, over time. So given that chronological age was
00:11:24 the outcome that the model was trying to predict, it's not really surprising that these clocks
00:11:28 became very good at estimating age often within kind of a few years of age. But at the same time,
00:11:35 And the fact that patterns of DNA methylation change consistently across ages of individuals,
00:11:43 that had a biological interest to it.
00:11:45 And it suggested that there might be certain areas in the genome where methylation shifts
00:11:52 occur in a predictable way as people get older.
00:11:55 Okay, so from a clinical standpoint, what does that tell us?
00:11:58 Well, estimating chronological age, which is what these first-generation clocks did,
00:12:03 wasn't adding any value because we already know chronological age. So it was more of a proof of
00:12:09 concept, but that's when the researchers realized, okay, what we really want to do is come up with
00:12:14 something that could be better than chronological age. And that's where this idea of biological age
00:12:19 could come from. And I just want to explain like sort of an extreme example of what this would
00:12:24 look like. So again, let's say you took two 60 year olds who I didn't tell you anything else 0.73
00:12:31 about them other than they're both 60 and they're, let's just say they're both the same sex. So two
00:12:35 60 year old women. So an actuarial table would say based on their chronological age, these women 0.98
00:12:43 both would have a life expectancy of, I'm making this up, 27 years. So if you're 60, your life
00:12:49 expectancy is 27 years, you're expected to live to 87. But if we could look at the methylation of
00:12:55 these two women and one of them came back and we were told, yes, but her biologic age is 65 and
00:13:02 the other one's biologic age is 55, the question is, does that delta of 10 years between them
00:13:11 actually translate to 10 years difference in lifespan? And so that's what these next generation
00:13:18 of clocks set out to do. Instead of predicting age, they started training on more clinically
00:13:24 meaningful outcomes. So they were trained on physiological biomarkers, data sets that would
00:13:31 be able to track mortality, and basically even things like rate of physiologic decline or pace
00:13:39 of aging. So the last category, this pace of aging one, I think is particularly interesting
00:13:44 because it aligns with what most people think they're getting when they look at a biologic
00:13:50 clock, which is not just how old am I, but how quickly am I aging right now? This topic came up,
00:13:55 by the way, in a podcast with Rich Miller, which was when they went back and looked at data from
00:14:02 the various ITP winners. So recall Rich Miller is the guy who oversees one of the parts of the
00:14:10 interventions testing program at the University of Michigan, where they take drugs like rapamycin,
00:14:15 metformin, nicotinamide, riboside, et cetera, they put them into mice over the duration of
00:14:21 their life. And then they look to see which of these drugs extend life. Well, they took all of
00:14:25 the ITP winners plus other things that were known to improve lifespan of mice, such as caloric
00:14:30 restriction. And they identified roughly a dozen or so, not epigenetic changes, but actual things
00:14:39 that showed up, proteins that showed up in those animals, something we would refer to as the
00:14:43 proteome, and they were able to generate in those mice predictive age rate calculators. So again,
00:14:51 a little too soon to tell if that's going to pan out in humans, but very interesting.
00:14:55 So many of these second-generation clocks were designed to predict outcomes like mortality by
00:15:02 incorporating methylation patterns that correlated with things like smoking exposure, inflammation,
00:15:06 and things like that. And while that's useful, it's important to understand that that kind of
00:15:11 changes how we interpret the output. So if a clock is particularly capturing a biological
00:15:16 fingerprint of something like smoking history or cardiometabolic health, then a shift in that
00:15:22 clock might reflect an improvement in that pathway. But it might reflect something really
00:15:28 uninteresting, like you're just recovering from a cold or you have lingering inflammation from
00:15:32 a heavy workout. So this is kind of where the excitement around aging clocks collides with
00:15:39 the reality of measurements, because there's basically two types of noise you have to consider
00:15:45 when you look at these clocks. You have to consider biological noise, which is the example I just gave
00:15:52 of how do I know that what you did in the day or week before didn't transiently impact what I'm
00:15:59 measuring, but truly has no impact on your health versus the measurement noise, which is how hard
00:16:07 is it to actually measure these things? So even in a very high quality lab, DNA methylation
00:16:13 measurements are not very stable. So variations can arise from a lot of things that how the sample
00:16:19 is handled and stored, differences in the methods for DNA extraction, you know, the efficiency of
00:16:26 the conversion steps that are used to read the methylation patterns, the batch effects on
00:16:32 methylation arrays themselves, and even differences in the mixture of immune cells present in the
00:16:39 blood at the time that the blood is drawn. Because remember, these are all being done not on tissue,
00:16:42 but on cells in the blood. And then on top of that, you know, the clocks are typically measuring
00:16:47 hundreds of thousands of methylation sites across the genome, and then trying to collapse all of
00:16:53 that information into a single summary score. And again, we love when we can do that, when we can
00:17:01 convert lots of data into a number, but we have to understand that we run risks of doing that.
00:17:06 So again, I'm not saying any of these things aren't challenges that maybe couldn't be overcome,
00:17:12 but I just want to make sure everybody understands like how, how technically complicated this is. So
00:17:17 again, just keep in mind biological noise and then technical or measurement noise. So basically
00:17:23 I think the reason these clocks are exciting is that they're kind of offering three things that
00:17:31 people want. So the first one I just kind of alluded to, which is compression. So aging is
00:17:37 very multi-dimensional. There are so many things that are going on. Your immune system is declining,
00:17:42 your fuel partitioning skills are declining, vascular health is declining, brain functions,
00:17:46 all these things are declining as we age on average, but the clocks are attempting to take
00:17:52 this and compress it into a single number. On the one hand, that's exciting. We love when we can do
00:17:58 things like that. BMI is a great example. Again, it's only combining height and weight, but it's
00:18:02 turning it into a single number. But we have to be mindful of the fact that the more you compress
00:18:09 something complicated, and BMI is a great example, it's only taking height and weight and compressing
00:18:14 it into a single number and trying to be a proxy for muscle mass, body fat, and things of those
00:18:19 nature. And here's the thing. On average, it's pretty good, right? At the population level,
00:18:24 BMI is pretty good. If I told you that in one city, the BMI average was 24, and in the other
00:18:31 city, the BMI average was 29, and I said, tell me which of those two cities do you think is healthier?
00:18:37 Again, knowing nothing else, you're all going to say 24, and you're almost assuredly right. 0.85
00:18:41 But if I told you I have an individual who's got a BMI of 24, and I have an individual whose BMI
00:18:47 is 29, tell me which one's healthier. Truth of the matter is, it's going to be tough. There are some
00:18:54 really unhealthy people with normal BMIs, and there are some really healthy people, usually quite
00:18:58 muscular, that have quite high BMIs. So this idea sort of falls apart, and you can imagine how much
00:19:04 more susceptible we would be to that when we're taking a much larger and more multi-dimensional
00:19:09 problem. Okay, the second big thing we want out of clocks is not just compression, but it's speed.
00:19:15 I kind of alluded to this at the outset, right? It would be amazing if we could do clinical trials
00:19:19 for a year and get the type of benefits in terms of insight that we would get if we were doing
00:19:26 these clinical trials for 20 years. The third one I also kind of alluded to already, which is at the
00:19:31 individual level, we want feedback. I want to know that if I changed my diet from this to that after
00:19:39 three months or six months, was that the right change to make? I want to know that if I'm taking
00:19:45 this supplement, which supposedly reduces inflammation and supposedly does several other
00:19:52 factors that are targeting hallmarks of aging, I want to know if it's doing it. So bottom line is,
00:19:59 this is why we want them. Question is, does it work? Okay. So the best way we could think to
00:20:05 talk about this is internally, meaning our research team, we looked at a couple of studies
00:20:11 that we thought really highlighted a couple of the important points here. And so that's what I
00:20:18 want to talk about here, these two studies. Okay. So the first study looked at an intervention.
00:20:24 It was a very simple intervention. They used omega-3 supplementation, vitamin D supplementation,
00:20:30 and exercise. And then they ask the question, will those simple interventions, and I'll talk
00:20:37 about them in a little bit more detail, move the needle on the four most common epigenetic
00:20:42 aging clocks in a randomized fashion? So, randomized people to these things measure on.
00:20:48 Second study that we're going to talk about takes a different approach, but asks if we can estimate
00:20:53 a person's pace of aging using structural features from a single brain MRI. So different
00:21:01 approach, but let's talk about them both. Okay, so let's start with the first study. This was
00:21:07 referred to as the DO-HEALTH study, and I think it's a reasonable use case example, okay? So again,
00:21:15 if an aging clock is going to be useful, the best case scenario is probably that it can detect
00:21:21 biological signals in a randomized control trial. So if you think back to, again, the problem we
00:21:26 started with, the endpoint you really care about is something like mortality or incidence of disease
00:21:32 like dementia or cardiovascular disease or cancer. And the interventions in this trial, which are,
00:21:38 you know, very reasonable things to propose, you're not going to figure out in a year or two
00:21:43 years or three years if they're having an impact on those things. But if you have a biological
00:21:47 clock that is true to those things, you're going to be in the, in the end zone. So what did the
00:21:52 study do? So the study took, you know, it was, it was a European large study. It was a two by two
00:21:57 by two factorial. So that means they tested these three interventions that I talked about. So
00:22:03 giving vitamin D, giving EPA, DHA, and assigning exercise. They tested them individually and in
00:22:10 combination. So each individual was then randomized to one of eight groups for the duration of the
00:22:16 study, which is a three-year duration study. The measurements were collected at baseline and then
00:22:20 at three years. So you've got a blood level at time zero and then at three years. So they looked
00:22:25 at nearly 800 generally healthy older adults. So everyone was 70 plus, mean age 75 from Switzerland.
00:22:35 About half of these individuals met the criteria for what we would call healthy aging. So they
00:22:40 were basically free of chronic diseases, disabilities, cognitive impairment, any other
00:22:45 limitations, and they were quite active. About 88% of these people reported regular physical
00:22:51 activity, and about 60% of these people reported exercising more than three days per week prior to
00:22:57 enrollment. Okay, so again, the interventions, 2,000 IU of vitamin D, a relatively modest amount
00:23:05 of EPA and DHA, so one gram a day that contained 330 milligrams of EPA, 660 milligrams of DHA,
00:23:14 and this was from marine algae. And then adherence for both the vitamin D and omega-3 levels was
00:23:21 assessed by changes in serum level. So they did have the ability to kind of go up or down based
00:23:26 on what they were measuring. And then on the activity front, they had a simple home-based
00:23:32 exercise regimen that consisted of mostly strength training, 30 minutes, three times a week.
00:23:39 And this was added on top of whatever you were doing at baseline. So whatever you're doing at
00:23:44 baseline, fine, but we add this. And then compliance was tracked with exercise diaries
00:23:48 and follow-up. So my first thought when I looked at this was these are kind of modest interventions.
00:23:53 You know, a gram of omega-3 is pretty low. 2,000 IU of vitamin D is not going to do much. And 90
00:23:59 minutes of exercise in people who are mostly already exercising, you know, I guess it depends
00:24:05 on what they're already doing. But truthfully, I would have thought that was the most interesting
00:24:09 thing. But none of these are Herculean things, especially when you combine it with the fact
00:24:13 that most of these participants were relatively healthy and physically active. So it's not clear
00:24:17 what you would see here. But that said, I think this trial was designed well, and it's a useful
00:24:24 way to test whether these aging clocks can detect subtle changes over time. So let's talk about the
00:24:29 tests, right? So again, time zero and time three years, they measured DNA methylation, and then
00:24:35 they applied these clocks. So let's talk about the clocks that they used, because I mentioned that
00:24:38 they used four next-gen clocks. So the first one is called PhenoAge. So this test uses methylation
00:24:45 data from about 500 CPG sites, and it's trained to reproduce a clinical biomarker score that
00:24:51 predicts mortality risk. So that biomarker score that I incorporate takes measurements beyond just
00:24:57 the CPGs. It looks at albumin, glucose, C-reactive protein, kidney function, white blood cell count,
00:25:04 and then the clock reflects the physiologic health rather than just sort of their chronological aid.
00:25:10 The next one is called GrimAge. This uses methylation data from about a thousand CPG
00:25:16 sites to estimate the level of plasma proteins that are linked to aging, such as GDF15, leptin,
00:25:25 PAI1, and also smoking exposure. So these methylation-derived biomarkers are then combined
00:25:33 with chronological age and sex to predict a time to death. So this is kind of an interesting one,
00:25:40 right? This is that one that would try to get at what I was saying earlier, which is
00:25:44 if you have a 60-year-old, the actuarial time to death expectation might be, you know,
00:25:51 I'd made up a number, but say 35 or 37 years. If you did a grim age on that person and it said
00:25:58 20 years, that would suggest to you that this person is much less healthy than the average
00:26:03 60-year-old. And if it said, no, 40 years, you would say, oh, this person's healthier than the
00:26:09 average person that you would expect to see that age. Okay. Then there's another one called Grim
00:26:13 Age 2, which is the same as Grim Age. It just has an updated set of biomarkers. So it's using
00:26:19 C-reactive protein and A1C along with some other refinements. And then you have another one called
00:26:26 the Dunedin-PACE estimate, which is really trying to estimate the rate of aging rather
00:26:33 than biological age.
00:26:35 So this uses the methylation patterns of 173 CPG sites.
00:26:40 So unlike the others, which were trained on cross-sectional areas, this is trained on
00:26:46 a longitudinal set of data across a population in New Zealand called Dunedin.
00:26:52 and that's what allowed them to track over time what the changes were and try to estimate this
00:27:02 if you will first derivative okay so we'll put in the show notes a table that just kind of
00:27:08 links to all of that so that you you can sort of keep that in mind and keep coming back to it
00:27:12 so just to summarize that the first three right which were the pheno age the grim age the grim
00:27:19 age too, those are ones that are kind of looking at biological age and trying to see if that can
00:27:24 be more predictive than chronological age. And then the Dunedin pace is designed to estimate
00:27:29 the pace of aging. Okay. So again, important distinction. And again, what does it matter,
00:27:35 right? The biological age might tell you that a person's physiology resembles that of a typical
00:27:40 person who's older or younger. That was the example I gave. The pace of aging is trying
00:27:45 to answer a slightly different question which is at the time of my measurement how fast is the
00:27:50 system deteriorating okay so let's talk about what the study found we'll link to the figures in the
00:27:59 show notes so you can go and actually see the figures yourself because I think the figures
00:28:02 sort of tell a thousand words right but basically they looked at what each of the four tests showed
00:28:12 and they have forest plots for each of them. And they look at each of the four different forest
00:28:17 plots for each of the interventions, combinations of, and thereabouts. So what I'll just call out
00:28:23 is what was significant. So the pheno-age study found significance, an effect size of 0.2,
00:28:33 for just the omega-3 intervention, and then for the omega-3 and the vitamin D intervention,
00:28:38 for omega-3 and exercise, and then for all treatments combined. When you looked at the
00:28:45 grim age by itself, just this first-gen grim age, it found no significance, no change across the
00:28:51 board in anything. When you looked at grim age 2, the only thing that showed significance
00:28:58 was omega-3 versus placebo. And when you looked at the Dunedin pace, the only thing that showed
00:29:06 significance was omega-3 versus placebo. So the bottom line here is on balance, you know,
00:29:14 the most consistent finding was that something about omega-3 supplementation moved the needle
00:29:20 in at least three of the four clocks. So the only clock that it didn't move the needle in was the
00:29:26 first gen grim age clock. Now that said, even though the omega-3 change showed consistency
00:29:33 in three of the four tests, the magnitude of the effect was quite small. So if you translate it
00:29:37 into something a little more intuitive, the effect corresponded to about three months of reduced
00:29:43 aging over three years, depending on which clock you look at. And again, I still actually think
00:29:48 that's a larger magnitude than I would affect, but maybe if you believe these clocks, the
00:29:53 translation is for people with really, really low omega-3 intake, you don't need much to move
00:29:59 the needle. The vitamin D supplementation, as I said, didn't really impact the clocks at all.
00:30:04 But again, given the dosage, I don't think that was surprising. 30% of these participants
00:30:08 had a baseline level below 20 nanograms per deciliter. So it's possible that just the 2000
00:30:15 IU wasn't enough to get them anywhere. And then exercise also failed to show an independent effect.
00:30:22 Again, I think context here matters. Remember, these participants were already physically
00:30:26 active at baseline. So it might be that for a study of this size and this duration, you weren't
00:30:33 going to see the effect unless you did it in people who were not active. So again, not sure
00:30:39 what to make of this. I think that the results of this study, you know, don't answer a ton of
00:30:44 questions. These interventions are quite common. Not sure if they were dosed correctly. I don't
00:30:50 recall, actually now that I think about it, what they pre-selected as their power analysis. In
00:30:55 other words to pick the sample size that they picked they had to assume a certain effect size
00:31:00 and it might be that the effect size was it was a real one but it was smaller that would mean it
00:31:05 might not be clinically significant but I suppose that the use case here is reasonable right which
00:31:13 is were there small molecular shifts over time in a in an otherwise well-controlled setting of
00:31:21 course it also begs the question though which of these clocks do you believe right because if you
00:31:27 think that grim age is the right clock then it would say none of these things mattered if you
00:31:32 pick pheno age you would say gosh everything mattered except for exercise and if you pick
00:31:39 grim age too you would say omega-3 was the only thing that mattered and the same with the need
00:31:43 pace so i still at least on a personal level don't know that i can tell which of these clocks makes
00:31:50 the most sense. Now, one potential advantage of using an aging clock is that it does give a
00:31:56 shared endpoint across different interventions. So if you at least believe that there's internal
00:32:02 consistency, you could feel maybe more comfortable that, okay, in an absolute sense, I don't know if
00:32:09 these changes are right, but I could figure out that, hey, I'm getting more bang for my buck doing
00:32:15 more cardio versus more resistance training or vice versa. So the other thing I think that we
00:32:20 don't know here is what the, what the measurement error was. So how much technical noise there was
00:32:26 in these. Um, we've talked about this earlier in the podcast, not this one, but previous episodes
00:32:31 where, you know, there are lots of folks out there that'll go and buy the same, you know,
00:32:35 multiple versions of the same test, take a blood sample, identical, you know, single blood sample,
00:32:41 and then spread it across multiple tests, and you get different results. And so, you know,
00:32:46 there are various reasons that that could be happening. It's not clear from this paper
00:32:49 exactly what their technical spread was, but my guess is there's more noise in these measurements
00:32:57 than, say, measuring a blood glucose, where the assay is much easier and much more standardized
00:33:02 lab-to-lab. You know, I still think that whether these clocks are actually capturing the biology
00:33:08 we care about well enough, I think that's an unresolved question. We can obviously ask
00:33:14 different questions with clocks, but with most medical research, we kind of focus on very
00:33:19 specific outcomes, right? We're going to look at muscle strength if we're testing resistance
00:33:23 training. We're going to look at blood pressure if you're looking at an antihypertensive drug or
00:33:28 LDL cholesterol if you're using a lipid-lowering drug. I like what the aging clocks are trying to
00:33:34 do because not all things are going to be measured in single parameters. And even if you do lower LDL
00:33:42 by itself, it would be nice to know how much of an impact is that having on my overall aging.
00:33:48 So I think maybe the most important thing here is that if an aging clock could allow a researcher
00:33:54 to ask a long-term question within a shorter trial, that alone to me is reason enough to do
00:34:00 this. And then everything else, whether we individually can use them, that those would be,
00:34:04 those would be fantastic. I think what I liked about this paper was that the authors didn't kind
00:34:09 of use just a single clock that gave them the answer they were hoping for. They pre-specified
00:34:14 four clocks. They showed the data for four clocks. We talked about the results, right? Three of the
00:34:19 four showed a benefit for omega-3. Again, is that because they're detecting using different CPG
00:34:25 sites? Is it because they're using different biomarkers? It's not, it's not, it's not clear.
00:34:29 The authors point out that this type of discordance is not unfamiliar. There's a very famous study called the Calorie Trial. This was run out of Pennington many years ago. Eric Robison, who's a previous guest on the podcast, actually was the PI for that. But the data set from Calorie has been used multiple times.
00:34:47 This was a calorie restriction study, and it showed that, so the calorie restriction
00:34:54 showed a reduction in pace of aging using the Dunedin pace clock, but it didn't affect
00:35:01 the pheno age or grim age, which were the, these other first generation clocks.
00:35:05 So again, this is not, this is not unusual.
00:35:08 So where does this leave us?
00:35:10 The first study, the DOE health trial, shows that aging clocks can detect small biological
00:35:16 changes in response to an intervention, and in this case it was omega-3 supplementation that
00:35:21 appeared to slightly slow several epigenetic clocks over three years. The second study,
00:35:27 the Dunedin-PAC-NI paper, showed that scientists could build new types of aging clocks, in this
00:35:33 case using structural brain imaging, that appear to capture meaningful patterns related to cognitive
00:35:38 decline, frailty, and even overall mortality. So taken together, these studies illustrate both the
00:35:45 promise and limitations of aging clocks. On the promising side, these clocks may help researchers
00:35:51 detect early biological signals in situations where traditional clinical outcomes would take
00:35:57 decades to measure. And I think that's incredibly valuable for aging research. Running a 20-year
00:36:03 prevention trial for every possible intervention, you know, simply isn't feasible. And the biomarkers
00:36:10 that capture aspects of the aging process could help us prioritize which ideas are worth testing
00:36:16 more rigorously and putting more resources into. But at the same time, these clocks are still
00:36:21 models, and models come with limitations. In fact, to quote a famous physicist, and it's debated if
00:36:28 it was Fermi who said this, all models are wrong, some are useful. But the question is, how useful
00:36:33 are these models? Well, different clocks capture different aspects of biology. Small shifts,
00:36:39 in the measurements don't necessarily translate into meaningful improvements in health outcomes.
00:36:45 And most importantly, we still don't know whether changing the clock actually changes
00:36:50 what we ultimately care about, things like disease risk, disability, or lifespan.
00:36:56 This uncertainty matters a lot when we move from research into consumer health.
00:37:02 Right now, aging clocks are increasingly being marketed as a tool for individuals,
00:37:07 something you can order online, track over time, and use to evaluate your own lifestyle changes.
00:37:14 Some of these companies even promise to improve your biological age with supplements that they
00:37:19 will conveniently sell to you as well. But based on the current evidence, it's not clear that these
00:37:25 numbers actually give consumers any actionable information. If your aging clock changes by a few
00:37:31 months, what should you do differently? Should you change your diet, your exercise program,
00:37:36 your medications, take more of the supplements? At this moment, the science as it stands does
00:37:45 not provide clear answers to those questions. And in many cases, we already have much more
00:37:50 reliable metrics that tell us about health and longevity risk. Things like blood pressure,
00:37:56 glucose, lipids, whether you're smoking or not, all the various metrics we have around physical
00:38:01 fitness, and body composition. These are not particularly glamorous biomarkers, but they have
00:38:08 something that aging clocks don't have yet. Decades of evidence linking them directly to real clinical
00:38:15 outcomes. In fact, if you take a step back for a moment, we've already solved a large part of the
00:38:21 problem that aging clocks are trying to address. There's a particular industry out there that is
00:38:29 so good at doing this that their formulas are proprietary. Life insurance companies have been
00:38:37 predicting mortality risk for decades using actuarial models based on these various factors.
00:38:44 In fact, I recently reached out to a senior member of a life insurance company,
00:38:50 And this person shared with me that if they ever see a deviation in expected premium payouts that exceed 1%, it would be considered the most unusual event they could imagine.
00:39:07 So that means that at the population level, they have to be able to predict mortality at a degree of accuracy that exceeds anything we can imagine.
00:39:20 And I further asked if they were using any of the commercially available or research-grade
00:39:27 biological clocks, and the answer was no. So I think that tells you something,
00:39:33 that these companies are still doing their jobs surprisingly well, and they don't use
00:39:40 any of the aging or biological clocks. They rely instead on the data that we understand.
00:39:47 So at least for me, I think about this as if someone were to offer a biological age score, it's worth asking them what that number is actually telling them. Is it telling them something new, or at best, is it just repackaging information you already have or understand?
00:40:06 So again, this is not to say that these clocks provide no value. They are fascinating scientifically, and they may become more valuable as research tools over time. They may evolve into clinically meaningful biomarkers over time. But right now, I would say they would be best viewed as experimental tools for studying aging, at least at a broad enough population level, but not as definitive health metrics for individual decision-making.
00:40:35 So if you're interested in your own longevity, the takeaway is quite simple. Instead of obsessing over whether your biological age is 42 or 45, it's probably much more productive to focus on the things you already know are going to matter, right? Staying active, eating a balanced diet, getting appropriate sleep, maintaining and measuring clinically validated biomarkers.
00:41:01 Now, again, they might not sound as flashy as biological age and the scores that are attached
00:41:05 to them, but they remain some of the most powerful tools that we have for improving
00:41:09 both lifespan and healthspan. And as aging research continues to evolve, perhaps one day
00:41:15 these biomarkers that we get out of these clocks will help guide those efforts even further.
00:41:21 But I think for now, it's safe to say that the fundamentals still matter most.
00:41:26 Thank you for listening to this week's episode of The Drive. Head over to peteratiamd.com
00:41:33 forward slash show notes if you want to dig deeper into this episode. You can also find me
00:41:39 on YouTube, Instagram, and Twitter, all with the handle peteratiamd. You can also leave us
00:41:45 review on Apple Podcasts or whatever podcast player you use. This podcast is for general
00:41:51 informational purposes only and does not constitute the practice of medicine, nursing,
00:41:55 or other professional healthcare services, including the giving of medical advice.
00:41:59 No doctor-patient relationship is formed. The use of this information and the materials linked to
00:42:05 this podcast is at the user's own risk. The content on this podcast is not intended to
00:42:10 be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard
00:42:16 or delay in obtaining medical advice from any medical condition they have, and they should
00:42:20 seek the assistance of their healthcare professionals for any such conditions. Finally,
00:42:25 I take all conflicts of interest very seriously. For all of my disclosures and the companies I
00:42:30 invest in or advise, please visit peteratiamd.com forward slash about where I keep an up-to-date
00:42:37 and active list of all disclosures.